Skip to content

8:30 am Coffee & Networking

8:55 am Chair’s Opening Remarks

Analyzing Tumor Target Selection to Maximize Efficacy Whilst Minimizing Toxicity

9:00 am Multi-functional Antibody-based Immunotherapies Enabling Precision Targeting of Tumor Cells and Transformation of the Local Immunological Environment

9:30 am Protease Dependent COBRA™ Activity Regresses Established Tumors in Mice

  • Chad May Senior Vice President - Research & Development, Maverick Therapeutics

Optimizing Next Generation Drug Discovery through Advances in Technology

10:00 am Improving CD3 Bi-Specific Therapeutic Responses through Combination Regimens and Molecular Design

  • Paul Moore VP, Cell Biology and Immunology , MacroGenics

10:30 am A Novel Class of Antibodies to Enhance CD3 Bispecific Activity in Solid Tumors

11:00 am Morning Refreshments

11:30 am The Next-Gen Bispecific Antibody Format for Development of Immunotherapies for the Treatment of Cancer

12:00 pm A T Cell-Engaging Antibody for Treatment of FLT3-expressing Leukemias

12:30 pm Networking Lunch

Analyzing the Biology of T cells, NK cells & the Tumor Microenvironment to Improve Cell Engager Therapies

1:30 pm IL-15 Containing Trispecific Killer Engagers (TriKETM) To Make NK Cells Antigen Specific

2:00 pm Comparing the Biology of Conditional Agonists Targeting CD3, the g9d2 TCR and NK Activation Receptors

2:30 pm Opening up the Tumor Microenvironment to Enable T cell Directed Therapies and more

3:00 pm Afternoon Refreshments & Networking

3:30 pm Bispecific γδ-T cell Engagers for Cancer Immunotherapy

Comparing Cell Engagers with CAR Therapeutics and Bispecifics

4:00 pm Benchmarking T Cell-Redirecting Therapies for Cancer: Comparing CD3Bispecifics and CAR T Cells

4:30 pm Design Strategies and Insights on the Activity of Cell Engagers with CAR Therapeutics and Bispecifics

5:00 pm Chair’s Closing Remarks & Close